Nemes Rush Group’s Novo Nordisk NVO Stock Holding History

Nemes Rush Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.88K	Sell	106 -112	-51%	-$5.31K	﹤0.01%	665
2025 Q4	$11.1K	Buy	218 +55	+34%	+$2.81K	﹤0.01%	536
2025 Q3	$9.02K	Sell	163 -17,961	-99%	-$1.05M	﹤0.01%	500
2025 Q2	$1.25M	Sell	18,124 -78,992	-81%	-$5.37M	0.14%	90
2025 Q1	$6.74M	Buy	97,116 +13,951	+17%	+$1.15M	0.85%	39
2024 Q4	$7.15M	Sell	83,165 -10,198	-11%	-$1.1M	0.88%	37
2024 Q3	$12M	Sell	93,363 -6,915	-7%	-$922K	1.74%	19
2024 Q2	$14.3M	Buy	100,278 +6,114	+6%	+$810K	1.97%	15
2024 Q1	$12.1M	Buy	94,164 +93,708	+20,550%	+$11.2M	1.73%	19
2023 Q4	$47.2K	Buy	456 +27	+6%	+$2.67K	0.01%	260
2023 Q3	$39K	Sell	429 -93	-18%	-$8.19K	0.01%	279
2023 Q2	$42.2K	Buy	+522	New	+$42.6K	0.01%	286

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Nemes Rush Group's NVO Position: Q1 2026 in Review

Nemes Rush Group reduced its Novo Nordisk (NVO) stake by 51% in Q1 2026, selling an estimated $5.31K and leaving 106 shares worth $3.88K. The position accounts for ﹤0.01% of the portfolio, ranked #665.

Nemes Rush Group first reported a position in NVO in Q2 2023 and has held it in 12 quarters since. The position peaked at $14.3M in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Nemes Rush Group held 106 shares of Novo Nordisk worth $3.88K as of Q1 2026.
Nemes Rush Group sold 112 Novo Nordisk shares in Q1 2026, an estimated $5.31K.
Novo Nordisk made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #665 holding.
Nemes Rush Group first reported a position in Novo Nordisk in Q2 2023 and has held it in 12 quarters since.
Nemes Rush Group's Novo Nordisk position peaked at $14.3M in Q2 2024.
1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.